Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

A new device is transforming the type of treatment some heart patients with atrial fibrillation receive. Doctors say it’s ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

The company states: “Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN FLX Left Atrial Appendage Closure Device ...

In late-breaking data presentations, the ADVANTAGE AF trial for the Farapulse PFA system met its primary endpoints, showing a 2.3% safety event rate and 63.5% effectiveness rate in treating persistent ...

Why it matters: The first year of rolling out Farapulse in the US has been a smashing success, and we think Boston has made the most of its opportunity to upset what had been the long-standing ...

Boston Scientific Corporation BSX recently presented data supporting the use of the FARAPULSE Pulsed Field Ablation (“PFA”) system and the WATCHMAN Left Atrial Appendage Closure (“LAAC ...

The company’s Electrophysiology (EP) arm continues to gain momentum on the sustained adoption of FARAPULSE PFA. The long-term prospects of the WATCHMAN devices are also encouraging. Meanwhile ...

Boston Scientific reported that electrophysiology sales grew 172% in Q4 2024, driven by an uptake of its Farapulse pulsed field ablation (PFA) system. Revealing its Q4 and full-year results ...